Multiple sclerosis (MS) is an autoimmune inflammatory disease of the central nervous system caused by a complex interaction between multiple genes and environmental factors. HLA region is the strongest susceptibility locus, but recent huge genome-wide association studies identified new susceptibility genes. Among these, BACH2, PTGER4, RGS1 and ZFP36L1 were highlighted. Here, a gene expression analysis revealed that three of them, namely BACH2, PTGER4 and ZFP36L1, are down-regulated in MS patients' blood cells compared to healthy subjects. Interestingly, all these genes are involved in the immune system regulation with predominant anti-inflammatory role and their reduction could predispose to MS development.
Introduction
Multiple sclerosis (MS) is a complex autoimmune inflammatory disease of the central nervous system (CNS) in which environmental and genetic factors converge with epigenetic and post-genomic regulatory events.
The leading role of genetic factors is supported by several studies of MS families (Robertson et al., 1996; Ebers et al., 2000) . The strongest susceptibility signal maps to the HLA-DRB1 gene in the class II region of the major histocompatibility complex (MHC) (Barcellos et al., 2006; Yeo et al., 2007) . Recently, the two largest genome-wide association studies (GWASs) of MS genetics confirmed HLA as the major MS susceptibility locus and provided unequivocal evidence for the association of additional 110 non-MHC "candidate" genetic variants conferring susceptibility to the disease (IMSGC et al., 2011 (IMSGC et al., , 2013 .
Notably, the majority of these novel MS-associated genes played pivotal roles in the workings of the immune system and were also associated with other autoimmune diseases, supporting the hypothesis that the same processes occur in different autoimmune diseases (Baranzini, 2009; Cotsapas et al., 2011) .
To investigate the mechanisms behind the regulation of inflammation in MS, we recently conducted a genome-wide transcriptional analysis of peripheral blood mononuclear cells (PBMC) obtained from treatment-naïve MS women and healthy controls (HC) before, during and after gestation. We identified a MS signature including 347 transcripts differently modulated in MS patients compared to HC before pregnancy (Gilli et al., 2010) . Among these, in this work we focused on those genes identified as novel MS risk loci in the above mentioned GWASs (IMSGC et al., 2011 (IMSGC et al., , 2013 . This approach highlighted 5 matching genes namely tumor necrosis factor alpha-induced protein 3 (TNFAIP3), BTB and CNC Homology 1 basic leucine zipper transcription factor 2 (BACH2), prostaglandin E receptor 4 (subtype EP4) (PTGER4), regulator of G-protein signaling 1 (RGS1), and zinc finger protein 36-C3H-type-like 1 (ZFP36L1). Interestingly, all these transcripts were previously reported as involved in the immune system regulation, mainly with an anti-inflammatory role (Hollinger and Hepler, 2002; Murn et al., 2008; Yao et al., 2009; Esaki et al., 2010; Sanduja et al., 2011; Roychoudhuri et al., 2013) and associated with several autoimmune diseases (Hunt et al., 2008; Grant et al., 2009; Perdigones et al., 2010; Medici et al., 2014) .
Since in our pilot study TNFAIP3 and ZFP36L1 expression reverted to normal in pregnant MS women, their levels were further investigated in a second population. Only TNFAIP3 deregulation was confirmed (Gilli et al., 2010) and subsequently validated in a larger study including also males, showing a correlation between TNFAIP3 levels and the disease clinical course (Gilli et al., 2011) .
Here, we focused on analyzing gene expression of the remaining genes BACH2, PTGER4, and RGS1 in treatment-naïve MS patients Journal of Neuroimmunology 279 (2015) [75] [76] [77] [78] 
